Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
CPT Pharmacometrics Syst Pharmacol ; 13(6): 1067-1078, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38676306

RESUMEN

Regulatory T cells (Tregs) are essential for maintaining immune homeostasis by serving as negative regulators of adaptive immune system effector cell responses. Reduced production or function of Tregs has been implicated in several human autoimmune diseases. The cytokine interleukin 2 plays a central role in promoting Treg differentiation, survival, and function in vivo and may therefore have therapeutic benefits for autoimmune diseases. mRNA-6231 is an investigational, lipid nanoparticle-encapsulated, mRNA-based therapy that encodes a modified human interleukin 2 mutein fused to human serum albumin (HSA-IL2m). Herein, we report the development of a semi-mechanistic kinetic-pharmacodynamic model to quantify the relationship between subcutaneous dose(s) of mRNA-6231, HSA-IL2m protein expression, and Treg expansion in nonhuman primates. The nonclinical kinetic-pharmacodynamic model was extrapolated to humans using allometric scaling principles and the physiological basis of pharmacological mechanisms to predict the clinical response to therapy a priori. Model-based simulations were used to inform the dose selection and design of the first-in-human clinical study (NCT04916431). The modeling approach used to predict human responses was validated when data became available from the phase I clinical study. This validation indicates that the approach is valuable in informing clinical decision-making.


Asunto(s)
Interleucina-2 , ARN Mensajero , Humanos , Interleucina-2/farmacocinética , Interleucina-2/genética , Interleucina-2/farmacología , Interleucina-2/administración & dosificación , Animales , ARN Mensajero/genética , Linfocitos T Reguladores/efectos de los fármacos , Nanopartículas , Modelos Biológicos , Masculino , Liposomas
2.
Ann N Y Acad Sci ; 1048: 505-8, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-16154987

RESUMEN

We studied antioxidative system, germination, growth, and flowering in vitro in Chenopodium rubrum seeds of different ages. Peroxidase, superoxide dismutase, and catalase activity, as well as glutathione status, were determined in 2.5-h imbibed seeds. Germination was tested under controlled conditions. Growth and flowering of plants were tested in vitro. The enzyme activities and glutathione content were higher in younger seeds. Germination declines with seed age. Plants derived from older seeds were smaller, and flowering percentage was lower compared to plants derived from younger seeds. Gibberellic acid reduced the difference in growth and flowering between plants derived from seeds different in age.


Asunto(s)
Envejecimiento/fisiología , Chenopodium/fisiología , Semillas/enzimología , Catalasa/metabolismo , Germinación , Giberelinas/metabolismo , Glutatión Peroxidasa/metabolismo , Peroxidasas/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Semillas/crecimiento & desarrollo , Superóxido Dismutasa/metabolismo
3.
J Clin Pharmacol ; 53(2): 178-91, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23436263

RESUMEN

A comprehensive analysis on the prediction of human clearance based on intravenous pharmacokinetic data from rat, dog, and monkey for approximately 400 compounds was undertaken. This data set has been carefully compiled from literature reports and expanded with some in-house determinations for plasma protein binding and rat clearance. To the authors- knowledge, this is the largest publicly available data set. The present examination offers a comparison of 37 different methods for prediction of human clearance across compounds of diverse physicochemical properties. Furthermore, this work demonstrates the application of each prediction method to each charge class of the compounds, thus presenting an additional dimension to prediction of human pharmacokinetics. In general, the observations suggest that methods employing monkey clearance values and a method incorporating differences in plasma protein binding between rat and human yield the best overall predictions as suggested by approximately 60% compounds within 2-fold geometric mean-fold error. Other single-species scaling or proportionality methods incorporating the fraction unbound in the corresponding preclinical species for prediction of free clearance in human were generally unsuccessful.


Asunto(s)
Evaluación Preclínica de Medicamentos , Farmacocinética , Animales , Perros , Haplorrinos , Humanos , Tasa de Depuración Metabólica , Ratas , Especificidad de la Especie
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA